Tariffs may not be the only tool at the federal government’s disposal to promote U.S. manufacturing of pharmaceuticals and medical devices. As the new administration continues to push for the onshore manufacturing of these products, the Bayh-Dole Act (the “Act”) could be another enforcement mechanism to bring life sciences manufacturing operations to the U.S., particularly for those products that relied on federal funding during research and development.

Read the full article on ABA Health Law Today.

Insight Industries + Practices